Investor Presentation

5 August 2026 To To BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400001 Bandra (E), Mumbai – 400051 Scrip Code: 543064 Scrip Symbol: COHANCE Dear Sir/Madam, Sub: Investor Presentation Please find annexed investor presentation on the unaudited financial results of the Company for the quarter ended 30 June 2026. We request you to take the above on record. Thanking you. Yours faithfully, For Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) Sisir K. Mishra Company Secretary & Compliance Officer Encl: as above Q1 FY2027 5th AUGUST 2026 This document and information herein is solely for information purposes and must not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. This document may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to media or reproduced in any form, without prior written consent Cohance Lifesciences This document is based on information obtained from public sources and sources believed to be reliable and information contained in this presentation concerning our industry, competitive position and the markets in which we operate is based on information from independent industry and research organizations, other third-party sources and management estimates Under no circumstances shall Cohance Lifesciences or its employees, consultants, agents or representatives be liable for any costs, expenses, losses, claims, liabilities, or other damages (whether direct, indirect, special, incidental, consequential, or otherwise) that may arise from, or be incurred in connection with, the content or any use thereof Awards & Recognition Executive summary and ESG 04 16 Business and Financial Business wise Strategy performance 06 20 Enhancing stake in sapala Annexure organics 13 31 EXECUTIVE SUMMARY Q1 FY27: PERFORMANCE IN LINE WITH COMMENTARY  As guided, Q1 was weak on revenue and EBITDA, reflecting shipment and order phasing, an unfavourable product mix, negative operating leverage and subsidiary consolidation. The standalone business remained strong and the balance sheet net-cash positive  Strategic initiatives: Management has acted on two immediate priorities—building one integrated nucleic-acid business with clear leadership and a defined path to full ownership of Sapala, and repositioning Agrochemicals towards a broader innovator-product-led portfolio  Pharma CDMO: Scheduled commercial deliveries, a secured restocking order and progress across the 10-molecule Phase III portfolio support recovery in small molecules. The focus in ADCs is an integrated payload–linker–bioconjugation offering and improved utilisation at NJ Bio; nucleic-acid capabilities are being unified around Sapala with a defined path to full ownership  API+: A resilient base supported by niche APIs, cost competitiveness, backward integration and a healthy order book. Priorities are disciplined execution, higher-value innovator lifecycle opportunities and progressive normalisation in Formulations  Specialty Chemicals: Agrochemicals is being repositioned towards a broader innovator-product-led portfolio, while Performance Materials remains stable and electronic and semiconductor-linked opportunities are being developed as longer-term growth drivers  The management focus remains on customer conversion, predictable delivery, quality, safety and better utilisation across the Cohance platform FY27 OUTLOOK: GROWTH YEAR, WEIGHTED TOWARDS H2  Sequential improvement is expected from Q2. Growth is expected to return during H2 FY27  Growth is expected to be supported by the recovery in Pharma CDMO, order-backed growth in Sapala, stability in API+ and normalisation in formulations  ADC payloads and linkers, AgChem and emerging Performance Chemicals programmes will strengthen the late-stage pipeline and build a broader base for growth beyond FY27  EBITDA improvement is expected to be weighted towards the second half, supported by volume recovery, a better product mix and improved utilisation across the platform BUSINESS AND FINANCIAL PERFORMANCE Q1 FY27 performance: Q1 FY27 Financial Highlights  Q1 FY27 revenues stood at INR 4,223 Mn, a decline of 23.1% YoY. This was on the back of shipment phasing in Pharma CDMO, a softer contribution from (23.1%) (10.4%) 2.5x Agrochemicals, lower Formulations revenue and the timing of execution across parts of the portfolio. It was partly offset by strong growth at Sapala and resilient API Revenue growth (YoY) API+ growth (YoY) Sapala revenue growth performance (YoY)  Our Niche technology share contributed 15.1% of revenues INR 4.22 Bn INR 92 mn* INR (430) mn*  API+ segment declined 10.4% YoY, largely due to timing-related factors. Certain commercial orders and validation campaigns shifted into later quarters, while one Total Revenue Adjusted EBITDA Adjusted Profit/(loss) after Tax program was affected by an operational event at a customer facility. Select parts of the portfolio saw lower volumes as well. Favorable pricing and an improved product 2.2% 9.2% 15.1% mix offset the impact on API+ business. Underlying demand remains healthy with a EBITDA% excl. one time Adjusted EBITDA standalone % Niche Tech as % of revenue robust API order book supporting our outlook for the year  Specialty Chemicals revenue declined by 34.7% YoY, primarily led by expected H2 dominated phasing of products in AgChem Segmental Revenue (YoY) – CDMO# share at 38%  Gross margins contracted to 71.5%, down 150 basis points YoY, largely due to product mix and a lower contribution from the CDMO business. Other costs such as higher freight, logistics and raw-material costs were partially mitigated via selective Pharma CDMO price pass-throughs to customers across business segments  Adjusted EBITDA for Q1 FY27 was INR 92 Mn, with margins at 2.2%. The sharp reduction reflects the lower revenue base, negative operating leverage and the impact of subsidiary consolidation from NJ Bio (made EBITDA loss of Rs. 328 Mn) Healthy cash generation in Q1FY27 API +  Free cash flow of INR 1,063 Mn generated during the quarter. Cash on books stood at Speciality INR 4,589 Mn, maintaining a healthy liquidity position Chemicals  INR 598 Mn capex deployed, as we continued investing in capabilities required for 8% future growth Note: #CDMO includes Pharma CDMO and Speciality Chemicals • Adjusted EBITDA is after One-time adjustment for ESOP, Merger and acquisition costs of Rs. 26 Mn in Q1FY27 Vs Rs. 171 Mn in Q1FY26 7 • Adjusted PAT is after One-time adjustment for ESOP, Merger and acquisition costs (Net of tax) INR Mn Particulars Q1FY26 Q1FY27 YoY • In Q1, CDMO (Pharma CDMO + Specialty Chemicals) share Revenue from Operations 5,493 4,223 -23.1% Material costs / COGS (1,481) (1,203) was 38%, all the business segments witnessed revenue Material Margin 4,012 3,020 -24.7% decline. Niche tech stood at 15.1% Material Margin % 73.0% 71.5% • Gross margins contracted by 150 bps YoY primarily due to Manufacturing Expenses (955) (934) Employee Cost (1,333) (1,330) increase in raw material cost and lower contribution from Other Expenses (604) (744) high margin CDMO segments offset by higher realisations and Total Expenses (2,892) (3,008) currency benefits EBIDTA (Reported) 1,120 12 -98.9% • Adjusted EBITDA margins were at 2.2%, highlighting the EBIDTA (Reported) % 20.4% 0.3% FX MTM gain 50 54 impact of lower revenue base, negative operating leverage Onetime expenses 171 26 and subsidiary consolidation EBIDTA (Adjusted) 1,341 92 -93.2% • Q2 will be better than Q1 and H2 will be better on a YOY basis EBIDTA (Adjusted) % 24.4% 2.2% Depreciation & Amortization (451) (495) Finance costs (101) (68) INR Mn Other income 91 68 Balance Sheet Highlights Profit/(loss) Before Tax (Adjusted) 880 (403) - As on 30th June 2026 Exceptional Items (81) 0 [Showing first 8,000 characters — download PDF for full document]